Vice Chair of Research, Chief of Breast Surgical Oncology
Duke University
Durham, North Carolina, United States
Dr. Hwang has been a faculty member of Duke University since 2011, serving as the Vice Chair of Research for the Department of Surgery since 2015 and the Mary and Deryl Hart Professor of Surgery and Co-Leader Women’s Cancer Program at the Duke Cancer Institute since 2018.
Dr. Hwang’s research focuses on breast cancer prevention; identifying less invasive treatments for early stage breast cancers including previnvasive cancer (DCIS); and understanding the genetic and stromal determinants of cancer progression. She also studies novel immune approaches to breast cancer treatment.
Dr. Hwang is active on the national stage, serving as a member of the National Cancer Institute Breast Cancer Steering Committee, National Comprehensive Cancer Network (NCCN) Guidelines Committees, and Co-Chair of the Human Tumor Atlas Network. In addition, she has participated in national and international panels and consortia to establish guidelines for DCIS, node-positive breast cancer, neoadjuvant therapy, and clinical trials endpoints for breast cancer. In 2016, she was honored as a Time 100 recipient for her innovative work in early stage breast cancer.
Dr. Hwang conducts clinical research and runs a basic science research lab focused on predictors of invasion in breast precancers. Her research is funded by grants from the National Institutes of Health (NIH), the National Cancer Institute, the Department of Defense, the Patient Centered Outcomes Research Institute (PCORI), the Breast Cancer Research Fund and others; Dr. Hwang was the top surgeon in NIH funding in 2018. She is principal investigator of three active NIH-funded grants, including the Pre-Cancer Atlas Research Centers (U2C) project, and the PCORI COMET trial, a multicenter study of active surveillance versus usual care for low-risk DCIS being conducted at over 80 study sites.
Astra Zeneca (Individual(s) Involved: Self): Consultant; Clinetic (Individual(s) Involved: Self): steering committee; Higgs Boson (Individual(s) Involved: Self): steering committee; Immunis (Individual(s) Involved: Self): Consultant; Merck (Individual(s) Involved: Self): speakers' bureau
Friday, March 11, 2022
10:11 AM – 10:19 AM CST
Friday, March 11, 2022
10:19 AM – 10:21 AM CST